ArticleLupus2022

Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.

Flavio Signorelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.